高级检索
当前位置: 首页 > 详情页

Efficacies of radiotherapy in rectal cancer patients treated with total mesorectal excision or other types of surgery: an updated meta-analysis

文献详情

资源类型:
WOS体系:

收录情况: ◇ ESCI

机构: [1]Hebei Univ Chinese Med, Hebei Prov Hosp Chinese Med, Dept Radiotherapy, Shijiazhuang, Peoples R China [2]China Acad Chinese Med Sci, Guanganmen Hosp, Dept Gastroenterol, Beijing, Peoples R China [3]Key Lab Integrated Chinese & Western Med Gastroent, Shijiazhuang, Peoples R China
出处:
ISSN:

关键词: rectal cancer radiotherapy concurrent chemoradiotherapy surgery TME

摘要:
Background An updated meta-analysis was conducted to evaluate the efficacy of radiotherapy in rectal cancer patients treated with total mesorectal excision (TME) or other types of surgery (non-TME-only). Methods The PubMed, Cochrane Library, and CNKI databases were searched. Data on overall survival (OS) were extracted. Results Hazard ratios (HRs) for OS associated with preoperative radiotherapy, preoperative long-course concurrent chemoradiotherapy (LCCRT), preoperative radiotherapy alone, and postoperative radiotherapy in patients treated with TME were 1.02 [95% CI: 0.92-1.14, P = 0.65], 1.04 [95% CI: 0.93-1.16, P = 0.47], 0.87 [95% CI: 0.61-1.25, P = 0.46], and 1.18 [95% CI: 0.91-1.52, P = 0.20], respectively. HRs for OS associated with preoperative radiotherapy, preoperative LCCRT, preoperative radiotherapy alone, preoperative long-course RT (LCRT), and preoperative short-course radiotherapy (SCRT) in patients treated with non-TME-only surgery were 0.85 [95% CI: 0.79-0.90, P < 0.00001], 0.77 [95% CI: 0.63-0.94, P = 0.009], 0.86 [95% CI: 0.80-0.92, P < 0.0001], 0.83 [95% CI: 0.73-0.95, P = 0.005], and 0.84 [95% CI: 0.77-0.91, P= <0.0001], respectively. The HR for postoperative radiotherapy in patients treated with non-TME-only surgery was 1.08 [95% CI: 0.84-1.39, P = 0.57]. Conclusion Preoperative radiotherapy, regardless of the regimen, improves the OS in patients treated with non-TME-only surgery, but not in those treated with TME. Postoperative radiotherapy does not improve OS.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2026]版:
最新[2025]版
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2025]版:
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2025版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Hebei Univ Chinese Med, Hebei Prov Hosp Chinese Med, Dept Radiotherapy, Shijiazhuang, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Hebei Univ Chinese Med, Hebei Prov Hosp Chinese Med, Dept Radiotherapy, Shijiazhuang, Peoples R China [3]Key Lab Integrated Chinese & Western Med Gastroent, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15714 今日访问量:0 总访问量:1038 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号